Risk Factors of Invasive Aspergillosis after Heart Transplantation: Protective Role of Oral Itraconazole Prophylaxis

American Journal of Transplantation

Volumn 4, Issue 4, 2004, Pages 636-643

  Muñoz, Patricia ^a   Rodríguez, Claudia ^a   Bouza, Emilio ^a   Palomo, Jesús ^a   Yañez, Juan F ^a   Domínguez, María Jesús ^a   Desco, Manuel ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Antifungal prophylaxis; Cardiac transplantation; CMV disease; Early and late outcome analysis; Heart transplantation; Hemodialysis; Invasive aspergillosis; Itraconazole; Odds ratio; Prophylaxis; Risk assessment modeling; Risk factors for infection

Indexed keywords

AZATHIOPRINE; CEFAZOLIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; GANCICLOVIR; HYPERIMMUNE GLOBULIN; ISONIAZID; ITRACONAZOLE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; AGED; ARTICLE; ASPERGILLOSIS; DRUG EFFICACY; FEMALE; HEART TRANSPLANTATION; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; REOPERATION; RISK FACTOR; SURVIVAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ITRACONAZOLE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RISK; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 1942469960     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2004.00390.x     Document Type: Article

References (63)

1. Cisneros JM, Muñoz P, Torre-Cisneros J et al. Pneumonia after heart transplantation: a multi-institutional study. Spanish Transplantation Infection Study Group. Clin Infect Dis 1998; 27: 324-331.
2. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases [published erratum appears in Rev Infect Dis 1991; 13: 345]. Rev Infect Dis 1990; 12: 1147-1201.
3. Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases [published erratum appears in Rev Infect Dis 1991; 13: 345]. Rev Infect Dis 1990; 12: 1147-1201.
4. Grossi P, Farina C, Fiocchi R, Dalla Gasperina D. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000; 70: 112-116.
5. Muñoz P, Torre-Cisneros J, Bouza E et al. Invasive aspergillosis in transplant recipients. A large multicentric study. In: Program and Abstracts of the 36th ICAAC (New Orleans), abstract 1416. Washington DC: American Society for Microbiology, 1996.
6. Muñoz P, Alcalá L, Sánchez M et al. The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis. Transplantation 2003; 75: 1-4.
7. Montoya JG, Giraldo LF, Efron B et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001; 33: 629-640.
8. Hofflin JM, Potasman I, Baldwin JC, Oyer PE, Stinson EB, Remington JS. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med 1987; 106: 209-216.
9. Hummel M, Thalmann U, Jautzke G, Staib F, Seibold M, Hetzer R. Fungal infections following heart transplantation. Mycoses 1992; 35: 23-34.
10. Schulman LL, Smith CR, Drusin R, Rose EA, Enson Y, Reemtsma K. Respiratory complications of cardiac transplantation. Am J Med Sci 1988; 296: 1-10.
11. Kaiser L, Huguenin T, Lew PD, Chapuis B, Pittet D. Invasive aspergillosis. Clinical features of 35 proven cases at a single institution. Medicine (Baltimore) 1998; 77: 188-194.
12. Muñoz P. Invasive aspergillosis in heart transplantation. http://www.aspergillus.man.ac.uk. 1999; Section of Treatment. Invasiveaspergillosis.
13. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999; 78: 123-138.
14. Singh N. Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy. Clin Infect Dis 2000; 31: 545-553.
15. Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis 1999; 1: 229-236.
16. Hibberd PL, Rubin RH. Clinical aspects of fungal infection in organ transplant recipients. Clin Infect Dis 1994; 19 (Suppl. 1): S33-S40.
17. Alexander BD. Prophylaxis of invasive mycoses in solid organ transplantation. Curr Opin Infect Dis 2002; 15: 583-589.
18. Utili R, Zampino R, De Vivo F et al. Improved outcome of pulmonary aspergillosis in heart transplant recipients with early diagnosis and itraconazole treatment. Clin Transplant 2000; 14: 282-286.
19. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001; 71: 910-913.
20. Muñoz P, Palomo J, Yañez J et al. Primary prophylaxis with itraconazole of invasive aspergillosis in heart transplant patients. In: Program and Abstracts of the 39th ICAAC (San Francisco), abstract 1416. Washington DC: American Society for Microbiology, 1999: 566.
21. Muñoz P, Palomo J, Muñoz R, Rodriguez Creixéms M, Pelaez T, Bouza E. Tuberculosis in heart transplant recipients. Clin Infect Dis 1995; 21: 398-402.
22. Muñoz P, Palomo J, Guembe P, Rodriguez-Creixems M, Gijon P, Bouza E. Lung nodular lesions in heart transplant recipients. J Heart Lung Transplant 2000; 19: 660-667.
23. Muñoz P, Muñoz RM, Palomo J, Rodriguez-Creixems M, Muñoz R, Bouza E. Pneumocystis carinii infection in heart transplant recipients. Efficacy of a weekend prophylaxis schedule. Medicine (Baltimore) 1997; 76: 415-422.
24. Patterson TF, Kirkpatrick WR, White M et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. 13 Aspergillus Study Group. Medicine (Baltimore) 2000; 79: 250-260.
25. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
26. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis 1996; 23: 608-615.
27. Briegel J, Forst H, Spill B et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995; 14: 375-382.
28. Collins LA, Samore MH, Roberts MS et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170: 644-652.
29. Kusne S, Torre-Cisneros J, Manez R et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis 1992; 166: 1379-1383.
30. Rogers J, Rohal S, Carrigan DR et al. Human herpesvirus-6 in liver transplant recipients: role in pathogenesis of fungal infections, neurologic complications, and outcome. Transplantation 2000; 69: 2566-2573.
31. Roilides E, Robinson T, Sein T, Pizzo PA, Walsh TJ. In vitro and ex vivo effects of cyclosporin A on phagocytic host defenses against Aspergillus fumigatus. Antimicrob Agents Chemother 1994; 38: 2883-2888.
32. Ori Y, Korzets A, Malachi T, Gafter U, Breitbart H. Impaired lymphocyte calcium metabolism in end-stage renal disease: enhanced influx, decreased efflux, and reduced response to mitogen. J Lab Clin Med 1999; 133: 391-400.
33. Magee C, Pascual M. The growing problem of chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 994-996.
34. Rabkin JM, Oroloff SL, Corless CL et al. Association of fungal infection and increased mortality in liver transplant recipients. Am J Surg 2000; 179: 426-430.
35. Dockrell DH, Mendez JC, Jones M et al. Human herpesvirus 6 seronegativity before transplantation predicts the occurrence of fungal infection in liver transplant recipients. Transplantation 1999; 67: 399-403.
36. Lorf T, Braun F, Ruchel R, Muller A, Sattler B, Ringe B. Systemic mycoses during prophylactical use of liposomal amphotericin B (Ambisome) after liver transplantation. Mycoses 1999; 42: 47-53.
37. Singh N, Gayowski T, Wagener MM. Posttransplantation dialysis-associated infections: morbidity and impact on outcome in liver transplant recipients. Liver Transpl 2001; 7: 100-105.
38. George MJ, Snydman DR, Werner BG et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103: 106-113.
39. Fortún J, Martín-Dávila P, Moreno S et al. Risk factors for invasive aspergillosis in liver transplant recipients. Liver Transpl 2002; 8: 1065-1070.
40. Monforte V, Roman A, Gavalda J et al. Nebulized amphotericin B prophylaxis for Aspergillus infection in lung transplantation: study of risk factors. J Heart Lung Transplant 2001; 20: 1274-1281.
41. Singh N, Avery RK, Muñoz P et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis 2003; 36: 46-52.
42. Wagner JA, Ross H, Hunt S et al. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation 1995; 60: 1473-1477.
43. Patterson JE, Peters J, Calhoon JH et al. Investigation and control of aspergillosis and other filamentous fungal infections in solid organ transplant recipients. Transpl Infect Dis 2000; 2: 22-28.
44. Slavin MA, Osborne B, Adams R et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-1552.
45. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donor for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962-968.
46. Rubin RH. The therapeutic prescription for the transplant, patient. Transpl Infect Dis 2002; 4: 1-2.
47. Singh N, Husain S. Aspergillus infections after lung transplantation: clinical differences in type of transplant and implications for management. J Heart Lung Transplant 2003; 22: 258-266.
48. Reichenspurner H, Gamberg P, Nitschke M et al. Significant reduction in the number of fungal infections after lung-, heart-lung, and heart transplantation using aerosolized amphotericin B prophylaxis. Transplant Proc 1997; 29: 627-628.
49. Viviani MA, Tortorano AM, Langer M et al. Experience with itraconazole in cryptococcosis and aspergillosis. J Infect 1989; 18: 151-165.
50. Faggian G, Livi U, Bortolotti U et al. Itraconazole therapy for acute invasive pulmonary aspergillosis in heart transplantation. Transplant Proc 1989; 21: 2506-2507.
51. Denning DW, Lee JY, Hostetler JS et al. NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis. Am J Med 1994; 97: 135-144.
52. Speich R, van der Bij W. Epidemiology and management of infections after lung transplantation. Clin Infect Dis 2001; 33 (Suppl. 1): S58-S65.
53. Thunnissen PL, Sizoo W, Hendriks WD. Safety and efficacy of itraconazole in prevention of fungal infections in neutropenic patients. Neth J Med 1991; 39: 84-91.
54. Colby WD, Sharpe MD, Ghent CN et al. Efficacy of itraconazole prophylaxis against systemic fungal infection in liver transplant recipients. In: 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco), abstract 1650. Washington, DC: American Society for Microbiology, 1999: 129.
55. Grossi P, De Maria R, Caroli A, Zaina MS, Minoli L. Infections in heart transplant recipients: the experience of the Italian heart transplantation program. Italian Study Group on Infections in Heart Transplantation. J Heart Lung Transplant 1992; 11: 847-866.
56. Bohme A, Just Nuebling G, Bergmann L, Shah PM, Stille W, Hoelzer D. Itraconazole for prophylaxis of systemic mycoses in neutropenic patients with haematological malignancies. J Antimicrob Chemother 1996; 38: 953-961.
57. Mouy R, Veber F, Blanche S et al. Long-term itraconazole prophylaxis against Aspergillus infections in thirty-two patients with chronic granulomatous disease. J Pediatr 1994; 125: 998-1003.
58. Keogh A, Spratt P, McCosker C, Macdonald P, Mundy J, Kaan A. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med 1995; 333: 628-633.
59. Menichetti F, Del Favero A, Martino P et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999; 28: 250-255.
60. Denning DW, Stepan DE, Blume KG, Stevens DA. Control of invasive pulmonary aspergillosis with oral itraconazole in a bone marrow transplant patient. J Infect 1992; 24: 73-79.
61. Caillot D, Casasnovas O, Bernard A et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139-147.
62. Patterson TF, Peters J, Levine SM et al. Systemic availability of itraconazole in lung transplantation. Antimicrob Agents Chemother 1996; 40: 2217-2220.
63. Prentice AG, Donnelly P. Oral antifungals as prophylaxis in haematological malignancy. Blood Rev 2001; 15: 1-8.